Compare · GNPX vs NTLA

GNPX vs NTLA

Side-by-side comparison of Genprex Inc. (GNPX) and Intellia Therapeutics Inc. (NTLA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. GNPX focuses on Biotechnology: Pharmaceutical Preparations, while NTLA focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances.
  • NTLA is the larger of the two at $1.34B, about 599.5x GNPX ($2.2M).
  • NTLA has been more active in the news (17 items in the past 4 weeks vs 9 for GNPX).
  • NTLA has more recent analyst coverage (25 ratings vs 0 for GNPX).
MetricGNPXNTLA
Company
Genprex Inc.
Intellia Therapeutics Inc.
Price
-
-
Market cap
$2.2M
$1.34B
1M return
-
-17.96%
1Y return
-
+18.78%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2018
2016
News (4w)
9
17
Recent ratings
0
25
GNPX

Genprex Inc.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

NTLA

Intellia Therapeutics Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Latest GNPX

Latest NTLA